<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font16 { font-size : 16; } .font17 { font-size : 17; } .font19 { font-size : 19; } .font25 { font-size : 25; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; }</style>
 <body>
  <p>
   <span class="font30">(-. </span>
   <span class="font25">weeks </span>
   <span class="font19">Low </span>
   <span class="font17">Propranolol </span>
   <span class="font16">Baseline </span>
   <span class="font16">Yes </span>
   <span class="font14">migraine </span>
   <span class="font14">-.) </span>
   <span class="font13">Migraine-episodic </span>
   <span class="font13">propranolol </span>
   <span class="font13">Headache </span>
   <span class="font13">Metoprolol </span>
   <span class="font12">Parallel </span>
   <span class="font12">headache </span>
   <span class="font12">Placebo </span>
   <span class="font12">Crossover </span>
   <span class="font12">Flunarizine </span>
   <span class="font12">CI: </span>
   <span class="font12">treatment </span>
   <span class="font11">study </span>
   <span class="font11">IHS </span>
   <span class="font11">beta-blockers </span>
   <span class="font11">migraine. </span>
   <span class="font11">Moderate </span>
   <span class="font11">metoprolol </span>
   <span class="font11">placebo </span>
   <span class="font11">trials </span>
   <span class="font11">Medicine </span>
   <span class="font11">Cephalalgia </span>
   <span class="font11">Nadolol </span>
   <span class="font11">trial </span>
   <span class="font11">Ad-hoc </span>
   <span class="font11">headaches </span>
   <span class="font11">./j.-...x </span>
   <span class="font11">prophylactic </span>
   <span class="font11">prophylaxis </span>
   <span class="font11">High </span>
   <span class="font11">Neurol </span>
   <span class="font11">Pindolol </span>
   <span class="font11">Topiramate </span>
   <span class="font11">outcomes </span>
   <span class="font10">flunarizine </span>
   <span class="font10">{border-style </span>
   <span class="font10">Amitriptyline </span>
   <span class="font10">chronic </span>
   <span class="font10">episodic </span>
   <span class="font10">tension-type </span>
   <span class="font10">Table </span>
   <span class="font10">effect </span>
   <span class="font10">frequency </span>
   <span class="font10">included </span>
   <span class="font10">px;} </span>
   <span class="font10">#ffffff;} </span>
   <span class="font10">Timolol </span>
   <span class="font10">USA </span>
   <span class="font10">analysis </span>
   <span class="font10">compared </span>
   <span class="font10">double-blind </span>
   <span class="font10">effective </span>
   <span class="font10">evidence </span>
   <span class="font10">Acid </span>
   <span class="font10">China </span>
   <span class="font10">Migraine </span>
   <span class="font10">Migraine-unspecified </span>
   <span class="font10">Quality </span>
   <span class="font10">comparisons </span>
   <span class="font10">migraine: </span>
   <span class="font10">studies </span>
   <span class="font10">using </span>
   <span class="font10">Germany </span>
   <span class="font10">Health </span>
   <span class="font10">Heterogeneity </span>
   <span class="font10">Med </span>
   <span class="font10">comparison </span>
   <span class="font10">Acta </span>
   <span class="font10">Bisoprolol </span>
   <span class="font10">CI) </span>
   <span class="font10">Sciences </span>
   <span class="font10">comparative </span>
   <span class="font10">prophylaxis. </span>
   <span class="font10">quality </span>
   <span class="font10">randomized </span>
   <span class="font10">reduction </span>
   <span class="font10">review </span>
   <span class="font10">topiramate </span>
   <span class="font10">trials. </span>
   <span class="font10">Acupuncture </span>
   <span class="font10">Comparison </span>
   <span class="font10">Fig </span>
   <span class="font10">Scand </span>
   <span class="font10">common </span>
   <span class="font10">controlled </span>
   <span class="font10">efficacy </span>
   <span class="font10">meta-analysis </span>
   <span class="font10">Atenolol </span>
   <span class="font10">Clinical </span>
   <span class="font10">Data </span>
   <span class="font10">Difference </span>
   <span class="font10">Mean </span>
   <span class="font10">effectiveness </span>
   <span class="font10">headache. </span>
   <span class="font10">single </span>
   <span class="font10">versus </span>
   <span class="font10">(RR: </span>
   <span class="font10">(mg) </span>
   <span class="font10">-., </span>
   <span class="font10">clinical </span>
   <span class="font10">including </span>
   <span class="font10">point </span>
   <span class="font10">primary </span>
   <span class="font10">(NS) </span>
   <span class="font10">Headaches </span>
   <span class="font10">data </span>
   <span class="font10">headaches/month </span>
   <span class="font10">network </span>
   <span class="font10">(HA </span>
   <span class="font10">Biofeedback </span>
   <span class="font10">Clonidine </span>
   <span class="font10">Cochrane </span>
   <span class="font10">Cyclandelate </span>
   <span class="font10">Epidemiology </span>
   <span class="font10">Frequency </span>
   <span class="font10">Hedman </span>
   <span class="font10">Neurology </span>
   <span class="font10">Norway </span>
   <span class="font10">Sweden </span>
   <span class="font10">Writing </span>
   <span class="font10">amitriptyline </span>
   <span class="font10">beta-blocker </span>
   <span class="font10">crossover </span>
   <span class="font10">effects </span>
   <span class="font10">headaches, </span>
   <span class="font10">likely </span>
   <span class="font10">placebo-controlled </span>
   <span class="font10">pooled </span>
   <span class="font10">preventing </span>
   <span class="font10">prophylaxis: </span>
   <span class="font10">reported </span>
   <span class="font10">Denmark </span>
   <span class="font10">Nifedipine </span>
   <span class="font10">Nimodipine </span>
   <span class="font10">Signs </span>
   <span class="font10">WFNRG </span>
   <span class="font10">Weighted </span>
   <span class="font10">acid </span>
   <span class="font10">baseline: </span>
   <span class="font10">combination </span>
   <span class="font10">curation </span>
   <span class="font10">duration </span>
   <span class="font10">editing </span>
   <span class="font10">number </span>
   <span class="font10">outcome </span>
   <span class="font10">patients </span>
   <span class="font10">prevention </span>
   <span class="font10">px; </span>
   <span class="font10">reduced </span>
   <span class="font10">results </span>
   <span class="font10">study. </span>
   <span class="font10">timolol </span>
   <span class="font10">{font-family </span>
   <span class="font10">(SMD: </span>
   <span class="font10">Behavioral </span>
   <span class="font10">Candesartan </span>
   <span class="font10">Chinese </span>
   <span class="font10">Department </span>
   <span class="font10">Management </span>
   <span class="font10">Nebivolol </span>
   <span class="font10">Time </span>
   <span class="font10">Tolfenamic </span>
   <span class="font10">analgesic </span>
   <span class="font10">assessed </span>
   <span class="font10">available </span>
   <span class="font10">combined </span>
   <span class="font10">commonly </span>
   <span class="font10">did </span>
   <span class="font10">disability </span>
   <span class="font10">font-size </span>
   <span class="font10">hours, </span>
   <span class="font10">impact </span>
   <span class="font10">mg) </span>
   <span class="font10">migraines </span>
   <span class="font10">nadolol </span>
   <span class="font10">reducing </span>
   <span class="font10">studied </span>
   <span class="font10">time </span>
   <span class="font10">trials, </span>
   <span class="font10">vs. </span>
   <span class="font10">(%) </span>
   <span class="font10">(headaches/month) </span>
   <span class="font10">.)) </span>
   <span class="font10">.), </span>
   <span class="font10">./journal.pone..t </span>
   <span class="font10">Chronic </span>
   <span class="font10">Comparative </span>
   <span class="font10">Femoxetine </span>
   <span class="font10">Headaches: </span>
   <span class="font10">Prophylactic </span>
   <span class="font10">Research </span>
   <span class="font10">Study </span>
   <span class="font10">Symptoms </span>
   <span class="font10">[], </span>
   <span class="font10">average </span>
   <span class="font10">bisoprolol </span>
   <span class="font10">different </span>
   <span class="font10">double; </span>
   <span class="font10">flunarizine, </span>
   <span class="font10">hoc </span>
   <span class="font10">low </span>
   <span class="font10">management </span>
   <span class="font10">month, </span>
   <span class="font10">provided </span>
   <span class="font10">similar </span>
   <span class="font10">use </span>
   <span class="font10">(.) </span>
   <span class="font10">(.–.) </span>
   <span class="font10">(RR) </span>
   <span class="font10">(baseline </span>
   <span class="font10">-.). </span>
   <span class="font10">.–.). </span>
   <span class="font10">Alprenolol </span>
   <span class="font10">American </span>
   <span class="font10">Aspirin </span>
   <span class="font10">Beta-blocker </span>
   <span class="font10">Clin </span>
   <span class="font10">Clomipramine </span>
   <span class="font10">Diener </span>
   <span class="font10">Episodic </span>
   <span class="font10">Europe </span>
   <span class="font10">Evidence </span>
   <span class="font10">Fluoxetine </span>
   <span class="font10">International </span>
   <span class="font10">Jackson </span>
   <span class="font10">Kangasniemi </span>
   <span class="font10">Linde </span>
   <span class="font10">Lipton </span>
   <span class="font10">Medical </span>
   <span class="font10">Nortriptyline </span>
   <span class="font10">Oxprenolol </span>
   <span class="font10">Rasmussen </span>
   <span class="font10">Riboflavin </span>
   <span class="font10">Severity </span>
   <span class="font10">Trial </span>
   <span class="font10">United </span>
   <span class="font10">Valproic </span>
   <span class="font10">Weeks </span>
   <span class="font10">based </span>
   <span class="font10">benefit </span>
   <span class="font10">bias </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">difference </span>
   <span class="font10">doses </span>
   <span class="font10">double-blind, </span>
   <span class="font10">given </span>
   <span class="font10">graded </span>
   <span class="font10">ha/month, </span>
   <span class="font10">important </span>
   <span class="font10">life </span>
   <span class="font10">medications </span>
   <span class="font10">month. </span>
   <span class="font10">pharmacologic </span>
   <span class="font10">reduce </span>
   <span class="font10">serotonin </span>
   <span class="font10">solid; </span>
   <span class="font10">systematic </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">-week </span>
   <span class="font10">.). </span>
   <span class="font10">.)/. </span>
   <span class="font10">./s--- </span>
   <span class="font10">.–., </span>
   <span class="font10">Analysis </span>
   <span class="font10">Controlled </span>
   <span class="font10">Diagnostic </span>
   <span class="font10">Diener, </span>
   <span class="font10">Grotemeyer </span>
   <span class="font10">Hartung </span>
   <span class="font10">India </span>
   <span class="font10">Italy </span>
   <span class="font10">JAMA </span>
   <span class="font10">Laboratory </span>
   <span class="font10">Medicine, </span>
   <span class="font10">Methods </span>
   <span class="font10">Migraines </span>
   <span class="font10">NNT: </span>
   <span class="font10">Naproxen </span>
   <span class="font10">Outcomes </span>
   <span class="font10">Pathology </span>
   <span class="font10">Pizotifen </span>
   <span class="font10">Prevalence </span>
   <span class="font10">Ryan </span>
   <span class="font10">Secondary </span>
   <span class="font10">Standardized </span>
   <span class="font10">Stewart </span>
   <span class="font10">Suppl </span>
   <span class="font10">Table. </span>
   <span class="font10">Tension-type </span>
   <span class="font10">Therapeutic </span>
   <span class="font10">Wang </span>
   <span class="font10">acid, </span>
   <span class="font10">additional </span>
   <span class="font10">antidepressants </span>
   <span class="font10">arm </span>
   <span class="font10">beta-blockers, </span>
   <span class="font10">bold </span>
   <span class="font10">clonidine, </span>
   <span class="font10">comparing </span>
   <span class="font10">conclusions </span>
   <span class="font10">courier; </span>
   <span class="font10">cross-over </span>
   <span class="font10">differences </span>
   <span class="font10">em; </span>
   <span class="font10">evaluated </span>
   <span class="font10">fluoxetine </span>
   <span class="font10">interventions </span>
   <span class="font10">low-quality </span>
   <span class="font10">migraine, </span>
   <span class="font10">pindolol </span>
   <span class="font10">placebo. </span>
   <span class="font10">prevalence </span>
   <span class="font10">previous </span>
   <span class="font10">propranolol, </span>
   <span class="font10">pt;} </span>
   <span class="font10">randomized, </span>
   <span class="font10">research </span>
   <span class="font10">sample </span>
   <span class="font10">secondary </span>
   <span class="font10">severity </span>
   <span class="font10">significant </span>
   <span class="font10">size </span>
   <span class="font10">specific </span>
   <span class="font10">trial. </span>
   <span class="font10">type </span>
   <span class="font10">unlikely </span>
   <span class="font10">used </span>
   <span class="font10">weeks. </span>
  </p>
 </body>
</html>
